Core Viewpoint - The company has proposed a cash dividend distribution plan for the first half of 2025, reflecting its profitability and commitment to shareholder returns [1][2][3]. Profit Distribution Plan - As of June 30, 2025, the company reported a net profit attributable to shareholders of 117,181,542.91 yuan, resulting in a total distributable profit of 372,964,159.44 yuan after accounting for previous distributions [1]. - The proposed cash dividend is 1.00 yuan per 10 shares, totaling 20,157,895.70 yuan, which represents 17.20% of the net profit for the first half of 2025 [2][3]. - The total number of shares for the dividend calculation is based on 201,578,957 shares after excluding treasury shares [2]. Approval Process and Legitimacy - The dividend proposal has been authorized by the 2024 annual general meeting, allowing the board to decide on the mid-year dividend based on actual conditions [2]. - The distribution plan complies with relevant regulations and the company's articles of association, ensuring its legality and reasonableness [3]. Additional Information - The company has taken measures to prevent insider trading and ensure confidentiality regarding the dividend proposal [3]. - The proposed distribution is designed to balance shareholder returns with the company's operational needs and long-term development [3].

格隆汇8月5日｜回盛生物公告，2025年上半年营业收入8.22亿元，同比增长88.45%；净利润1.17亿元， 同比增长325.88%。公司拟向全体股东每10股派发现金红利1元(含税)。 ...

回盛生物公告，2025年上半年营业收入8.22亿元，同比增长88.45%。净利润1.17亿元，同比增长 325.88%。公司拟向全体股东每10股派发现金红利1元（含税）。 ...

Market Overview - The animal health sector increased by 1.46% on August 5, with Shenlian Biological leading the gains [1] - The Shanghai Composite Index closed at 3617.6, up 0.96%, while the Shenzhen Component Index closed at 11106.96, up 0.59% [1] Stock Performance - Shenlian Biological (688098) closed at 8.83, up 10.79% with a trading volume of 410,700 shares and a turnover of 348 million yuan [1] - Xianfeng Holdings (002141) closed at 3.81, up 4.10% with a trading volume of 732,700 shares and a turnover of 280 million yuan [1] - Jinhai Biological (002688) closed at 7.60, up 3.54% with a trading volume of 645,200 shares and a turnover of 487 million yuan [1] - Huisheng Biological (300871) closed at 24.82, up 1.85% with a trading volume of 260,400 shares and a turnover of 636 million yuan [1] Capital Flow - The animal health sector saw a net inflow of 138 million yuan from institutional investors, while retail investors experienced a net outflow of 127 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors showing confidence while retail investors are withdrawing [2] Individual Stock Capital Flow - Jinhai Biological had a net inflow of 40.62 million yuan from institutional investors, while retail investors had a net outflow of 29.52 million yuan [3] - Huisheng Biological saw a net inflow of 36.65 million yuan from institutional investors, but a significant outflow of 74.58 million yuan from retail investors [3] - Shenlian Biological experienced a net inflow of 18.09 million yuan from institutional investors, with retail investors withdrawing 20.78 million yuan [3]

Investment Rating - The report maintains a "Recommended" rating for the agricultural, forestry, animal husbandry, and fishery industry [1][8]. Core Viewpoints - The report highlights a long-term revaluation opportunity for the pig industry, indicating that while pig prices are experiencing fluctuations, there is still downward pressure. The industry is expected to transition towards a self-regulatory and stable phase, benefiting leading companies such as Wens Foodstuffs, Muyuan Foods, and Juxing Agriculture [4][14]. - The poultry sector is currently facing low prices, but there are signs of marginal improvement in the cycle, with recommendations for companies like Shennong Development and Lihua Stock [5][24]. - The animal health sector is anticipated to see performance recovery and investment opportunities in pet medical services, with a focus on companies like Kexin Biological and Ruipuhua [6][34]. - The planting sector is experiencing a decline in the pig-to-grain price ratio, with ongoing commercialization of genetically modified seeds benefiting early adopters [7][37]. - The feed sector is witnessing price fluctuations, with recommendations for Haida Group and attention to He Feng Stock [7][42]. - The pet economy is thriving, with domestic brands gaining strength, and the report recommends companies in the pet food sector such as Guibao Pet and Zhongchong Stock [7][51]. Summary by Sections Pig Industry - The average price of pigs is currently around 14.08 yuan/kg, with fluctuations noted [14]. - The number of breeding sows has increased slightly, indicating a stable supply [14]. - Key recommendations include Wens Foodstuffs, Muyuan Foods, and Juxing Agriculture, with a suggestion to pay attention to Dekang Agriculture [4][14]. Poultry Industry - The price of white feather chicken is low, with a focus on potential marginal improvements in the cycle [5][23]. - The report notes a significant update in the breeding stock, with a mix of imported and self-bred varieties [5][24]. - Recommended companies include Shennong Development and Lihua Stock [5][24]. Animal Health - The report anticipates continued recovery in animal health companies' performance, supported by stable profits in the pig farming sector [6][34]. - The approval of mRNA vaccines for veterinary use marks a significant technological advancement [6][34]. - Recommended companies include Kexin Biological and Ruipuhua, with additional attention to Huisheng Biological and Jinhai Biological [6][34]. Planting Sector - The pig-to-grain price ratio has decreased, with ongoing commercialization of genetically modified seeds [7][37]. - Recommendations include Suqian Agricultural Development and Longping High-Tech [7][37]. Feed Sector - Feed prices are experiencing fluctuations, with specific prices noted for different types of feed [7][42]. - The report suggests that the feed industry is likely to see increased concentration, recommending Haida Group and monitoring He Feng Stock [7][42]. Pet Industry - The pet market is growing, with a significant increase in consumption and brand development [7][51]. - Recommendations include Guibao Pet, Zhongchong Stock, and Peidi Stock in the pet food sector, as well as Ruipuhua in the pet medical sector [7][51].

Market Overview - The animal health sector increased by 0.65% on August 4, with BioShares leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] Stock Performance - BioShares (600201) closed at 8.75, rising by 2.70% with a trading volume of 327,100 shares and a turnover of 280 million yuan [1] - Jinhe Biology (002688) closed at 7.34, up 2.51%, with a trading volume of 666,900 shares and a turnover of 485 million yuan [1] - Ruipu Biology (300119) closed at 21.58, increasing by 1.27%, with a trading volume of 72,800 shares and a turnover of 155 million yuan [1] - KQ Biology (688526) closed at 17.00, up 1.01%, with a trading volume of 29,600 shares and a turnover of 49.88 million yuan [1] - Other notable stocks include Dayu Biology (871970) at 10.40 (+0.97%) and Zeng Caike (603566) at 15.00 (+0.87%) [1] Capital Flow - The animal health sector saw a net inflow of 68.12 million yuan from institutional investors, while retail investors experienced a net outflow of 58.45 million yuan [2] - The main capital inflow and outflow for specific stocks include: - Jinhe Biology: 70.12 million yuan inflow from main investors, 33.36 million yuan outflow from retail investors [3] - BioShares: 15.45 million yuan inflow from main investors, 8.61 million yuan outflow from retail investors [3] - Shilian Biology (688098): 3.79 million yuan inflow from main investors, 27.89 million yuan outflow from retail investors [3]

Investment Rating - The report maintains a "Buy" rating for the agricultural, forestry, animal husbandry, and fishery sector, indicating an expected investment return exceeding 15% over the next 6-12 months [5]. Core Insights - The report highlights a strong rebound in meat and poultry prices due to increased stocking and the arrival of the consumption peak season [1][2]. - The pig price has shown a week-on-week increase of 1.27%, with the average price reaching 14.33 yuan/kg as of August 1 [23]. - The white feathered chicken price rose by 1.94% to 6.83 yuan/kg, while chick prices surged by 33.16% to 2.57 yuan/bird, driven by limited market supply and increased stocking enthusiasm among farmers [2][35]. - Corn and wheat prices have decreased slightly, while soybean meal prices have increased, indicating mixed trends in feed costs [3][50]. Summary by Sections 1. Market Overview - The agricultural sector underperformed against the broader market, with the agricultural index declining by 2.97% [14]. - The animal husbandry segment saw a significant drop, particularly in pig farming, which fell by 4.63% [14]. 2. Key Data Tracking - Pig prices increased to 14.33 yuan/kg, while the average weight of pigs at slaughter was 127.98 kg, reflecting a slight decrease [22][23]. - The white feathered chicken price reached 6.83 yuan/kg, and chick prices rose significantly, indicating a recovery in the poultry market [35][21]. - Yellow chicken prices improved due to seasonal demand, with medium-speed chicken prices increasing by 8.33% to 5.46 yuan/jin [45]. 3. Investment Recommendations - The report recommends focusing on the pig farming sector, anticipating a favorable supply-demand balance in August, with key companies to watch including Muyuan Foods, Wens Foodstuff Group, and Juxing Agriculture [4][71]. - For the feed and veterinary sectors, companies like Haida Group and Reap Bio are highlighted due to rising demand from increased pig stocks [4][71]. - In the planting chain, companies such as Suqian Agricultural Development and Beidahuang are recommended as grain prices are expected to rise [4][71]. - The pet food sector is also noted for growth potential, with companies like Guibao Pet and Zhongchong Co. being highlighted [4][74].

Group 1 - The core viewpoint of the news is that Jinhe Biology (002688.SZ) reported significant growth in its financial performance for the first half of 2025, with a notable increase in both revenue and net profit [1] - In the first half of 2025, the company's operating revenue reached 1.39 billion yuan, representing a year-on-year growth of 30.45%, while the net profit attributable to shareholders was 138 million yuan, up 51.52% [1] - The growth in performance is attributed to the company's focus on its core animal health business, which has established a dual-driven model of veterinary pharmaceuticals and vaccines, supported by environmental protection and agricultural product processing [1] Group 2 - In 2024, Jinhe Biology reported an operating revenue of 2.37 billion yuan, reflecting a year-on-year increase of 9.04%, and a net profit attributable to shareholders of 100 million yuan, which is a 15.90% growth [3] - The chairman of Jinhe Biology, Wang Dongxiao, is 73 years old and holds a graduate degree, also serving in various leadership roles in related companies [3] - Wang Dongxiao's compensation from 2020 to 2024 has shown slight fluctuations, with amounts of 943,200 yuan, 945,100 yuan, 844,800 yuan, 880,500 yuan, and 873,000 yuan respectively [3]

Core Viewpoint - The company Jinhe Biological has shown significant growth in its operating performance, with a notable increase in revenue and net profit in the first half of 2025, driven primarily by its veterinary pharmaceutical segment [1][2]. Financial Performance - In the first half of 2025, the company achieved revenue of 1.39 billion yuan, representing a year-on-year growth of 30.45% [1][2]. - The net profit for the same period reached 138 million yuan, marking a year-on-year increase of 51.52% [1][2]. - The gross profit margin improved to 34.55%, up 1.25 percentage points from the previous year, due to effective cost control [2]. Business Segments - The veterinary pharmaceutical segment is the core driver of growth, with revenue from this segment reaching 860 million yuan in the first half of 2025, a substantial increase of 72.15% year-on-year, accounting for 61.83% of total revenue [1][2]. - The company has established a diversified product matrix in the veterinary pharmaceutical field, focusing on the core product of premixed gentamicin [3][4]. Market Expansion - Jinhe Biological's overseas business generated revenue of 588 million yuan in the first half of 2025, reflecting a year-on-year growth of 65.5% and accounting for 42.3% of total revenue [3]. - The company has successfully penetrated over 10 countries and regions, with the United States being the largest overseas market, representing approximately two-thirds of its exports [3]. Research and Development - The company has invested a total of 529 million yuan in research and development over the past five and a half years, with a significant increase in R&D spending in 2025 [4][5]. - Jinhe Biological has established two major research centers for animal vaccines and has developed a rich product portfolio, including 16 vaccine products covering various animal types [5].

Core Viewpoint - Jinhe Biology demonstrated strong financial performance in the first half of 2025, with significant revenue and profit growth, particularly in the veterinary chemical drug sector [2][11]. Financial Overview - Total revenue reached 1.39 billion yuan, a year-on-year increase of 30.45% [2]. - Net profit attributable to shareholders was 138 million yuan, up 51.52% year-on-year [2]. - The second quarter saw total revenue of 765 million yuan, a 40.05% increase, and net profit of 86.8 million yuan, growing by 89.2% [2]. Profitability - The company's gross margin improved to 34.55%, an increase of 3.76% year-on-year [3]. - Net profit margin rose to 9.92%, up 16.73% year-on-year, indicating effective cost control and enhanced product value [3]. Costs and Expenses - Total operating expenses amounted to 279 million yuan, accounting for 20.03% of revenue, an increase of 2.32% year-on-year [4]. - Management expenses grew by 36.2%, primarily due to salary increases, depreciation from completed projects, and increased stock incentive costs [4]. - Financial expenses rose by 46.74%, attributed to interest expenses from completed projects and reduced foreign exchange gains in the previous year [4]. Cash Flow and Debt Situation - Cash and cash equivalents decreased to 625 million yuan, down 5.21% year-on-year [5]. - Operating cash flow per share was 0.17 yuan, a decline of 20.08% [5]. - Net cash flow from financing activities dropped by 95.88%, and net increase in cash and cash equivalents fell by 89.9% [5]. - Interest-bearing liabilities increased to 2.528 billion yuan, up 0.72% year-on-year, with an interest-bearing asset-liability ratio of 41.41% [5]. Accounts Receivable - Accounts receivable stood at 590 million yuan, a year-on-year increase of 22.22%, with a ratio to profit of 589.11%, indicating a need to monitor collection [6]. Main Business Analysis - The veterinary chemical drug segment generated 860 million yuan, accounting for 61.83% of total revenue, with a gross margin of 38.13% [7]. - Revenue from starch and related products was 275 million yuan, making up 19.76% of total revenue, with a gross margin of 11.15% [7]. - Veterinary vaccine revenue reached 155 million yuan, representing 11.12% of total revenue, with a gross margin of 54.87% [7]. - Environmental services contributed 69.13 million yuan, accounting for 4.97% of total revenue, with a gross margin of 44.25% [7]. Regional Distribution - Domestic sales revenue was 802 million yuan, accounting for 57.67% of total revenue, with a gross margin of 26.59% [8]. - International sales revenue reached 588 million yuan, making up 42.33% of total revenue, with a gross margin of 45.40% [8]. Development Strategy - The company focuses on its core animal health business, with a dual-driven model of veterinary pharmaceuticals and vaccines, supported by environmental and agricultural processing sectors [9]. - The completion of the sixth phase project added 60,000 tons of production capacity for key products, enhancing competitiveness through cost reduction and improved fermentation indices [9]. - The veterinary vaccine business has rapidly established a comprehensive industry layout through self-built and acquired production bases and R&D centers [9].